Utility of routine post-therapy surveillance imaging in diffuse large B-cell lymphoma

Journal of Clinical Oncology

Volumn 32, Issue 31, 2014, Pages 3506-3512

  Thompson, Carrie A ^a   Ghesquieres, Herve ^b   Maurer, Matthew J ^a   Cerhan, James R ^a   Biron, Pierre ^b   Ansell, Stephen M ^a   Chassagne Clément, Catherine ^b   Inwards, David J ^a   Gargi, Thérèse ^b   Johnston, Patrick B ^a   Nicolas Virelizier, Emmanuelle ^b   Macon, William R ^a   Peix, Marie ^b   Micallef, Ivana N ^a   Sebban, Catherine ^b   Nowakowski, Grzegorz S ^a   Porrata, Luis F ^a   Weiner, George J ^c   Witzig, Thomas E ^a   Habermann, Thomas M ^a   Link, Brian K ^c   more..

^a MAYO CLINIC   (United States)

^b CENTRE LÉON BÉRARD   (France)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; LACTATE DEHYDROGENASE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; COMPUTER ASSISTED TOMOGRAPHY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; FRANCE; HUMAN; INTERNATIONAL PROGNOSTIC INDEX; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR EPIDEMIOLOGY; PHYSICAL EXAMINATION; POSITRON EMISSION TOMOGRAPHY; TREATMENT OUTCOME; ADOLESCENT; CANCER STAGING; EPIDEMIOLOGY; LYMPH NODE METASTASIS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; RADIOGRAPHY; REMISSION; SURVIVAL RATE; TUMOR RECURRENCE; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; FRANCE; HUMANS; LYMPHATIC METASTASIS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84911476792     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.7561     Document Type: Article

References (30)

1. Morton LM, Turner JJ, Cerhan JR, et al: Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 110:695-708, 2007
2. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63:11-30, 2013
3. Philip T, Guglielmi C, Hagenbeek A, et al: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 333:1540-1545, 1995
4. Abel GA, Vanderplas A, Rodriguez MA, et al: High rates of surveillance imaging for treated diffuse large B-cell lymphoma: Findings from a large national database. Leuk Lymphoma 53:1113-1116, 2012
5. Guppy AE, Tebbutt NC, Norman A, et al: The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 44:123-125, 2003
6. Weeks JC, Yeap BY, Canellos GP, et al: Value of follow-up procedures in patients with large-cell lymphoma who achieve a complete remission. J Clin Oncol 9:1196-1203, 1991
7. El-Galaly T, Prakash V, Christiansen I, et al: Efficacy of routine surveillance with positron emission tomography/computed tomography in aggressive non-Hodgkin lymphoma in complete remission: Status in a single center. Leuk Lymphoma 52:597-603, 2011
8. Nakamura K, Sasaki M, Kunitake N, et al: Relapse patterns of localized non-Hodgkin's lymphoma of the head and neck after clinical remission: Results of a strict follow-up procedure. Int J Clin Oncol 6:302-305, 2001
9. Liedtke M, Hamlin PA, Moskowitz CH, et al: Surveillance imaging during remission identifies a group of patients with more favorable aggressive NHL at time of relapse: A retrospective analysis of a uniformly-treated patient population. Ann Oncol 17:909-913, 2006
10. Goldschmidt N, Or O, Klein M, et al: The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. Ann Hematol 90:165-171, 2011
11. Elis A, Blickstein D, Klein O, et al: Detection of relapse in non-Hodgkin's lymphoma: Role of routine follow-up studies. Am J Hematol 69:41-44, 2002
12. Cheah CY, Hofman MS, Dickinson M, et al: Limited role for surveillance PET-CT scanning in patients with diffuse large B-cell lymphoma in complete metabolic remission following primary therapy. Br J Cancer 109:312-317, 2013
13. National Comprehensive Cancer Network: The NCCN Non-Hodgkin Lymphoma Clinical Practice Guidelines in Oncology (Version 1.2013): http://www.nccn.org
14. Lerner RE, Thomas W, Defor TE, et al: The International Prognostic Index assessed at relapse predicts outcomes of autologous transplantation for diffuse large-cell non-Hodgkin's lymphoma in second complete or partial remission. Biol Blood Marrow Transplant 13:486-492, 2007
15. Hamlin PA, Zelenetz AD, Kewalramani T, et al: Age-adjusted International Prognostic Index predicts autologous stem cell transplantation outcome for patients with relapsed or primary refractory diffuse large B-cell lymphoma. Blood 102:1989-1996, 2003
16. Zinzani PL, Stefoni V, Tani M, et al: Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol 27:1781-1787, 2009
17. Petrausch U, Samaras P, Haile SR, et al: Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after firstline therapy. Ann Oncol 21:1694-1698, 2010
18. Hong J, Kim JH, Lee KH, et al: Symptomoriented clinical detection versus routine imaging as a monitoring policy of relapse in patients with diffuse large B-cell lymphoma. Leuk Lymphoma [e-pub ahead of print on March 7, 2014]
19. El-Galaly TC, Mylam KJ, Bogsted M, et al: Role of routine imaging in detecting recurrent lymphoma: A review of 258 patients with relapsed aggressive non-Hodgkin and Hodgkin lymphoma. Am J Hematol 89:575-580, 2014
20. Thompson CA, Charlson ME, Schenkein E, et al: Surveillance CT scans are a source of anxiety and fear of recurrence in long-term lymphoma survivors. Ann Oncol 21:2262-2266, 2010
21. Brenner DJ, Hall EJ: Computed tomography-an increasing source of radiation exposure. N Engl J Med 357:2277-2284, 2007
22. Shenoy P, Sinha R, Tumeh JW, et al: Surveillance computed tomography scans for patients with lymphoma: Is the risk worth the benefits? Clin Lymphoma Myeloma Leuk 10:270-277, 2010
23. Avivi I, Zilberlicht A, Dann EJ, et al: Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era. Am J Hematol 88:400-405, 2013
24. Drake MT, Maurer MJ, Link BK, et al: Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. J Clin Oncol 28:4191-4198, 2010
25. Maurer MJ, Micallef INM, Cerhan JR, et al: Elevated serum free light chains are associated with event-free and overall survival in two independent cohorts of patients with diffuse large B-cell lymphoma. J Clin Oncol 29:1620-1626, 2011
26. Institut Nacional du Cancer: Hematologic malignancies: Health professionals [in French]. http://www.e-cancer.fr/soins/recommandations/cancershematologiques
27. Habermann TM, Weller EA, Morrison VA, et al: Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 24:3121-3127, 2006
28. Gray RJ: A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
29. Lin T-L, Kuo M-C, Shih L-Y, et al: Value of surveillance computed tomography in the follow-up of diffuse large B-cell and follicular lymphomas. Ann Hematol 91:1741-1745, 2012
30. Miglioretti D, Johnson E, Williams A: The use of computed tomography in pediatrics and the associated radiation exposure and estimated cancer risk. JAMA Pediatrics: 1-8, 2013